These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1699945)

  • 1. Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.
    Osswald H; Frank N
    J Cancer Res Clin Oncol; 1990; 116(5):448-52. PubMed ID: 1699945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
    Wampler GL; Carter WH; Campbell ED; Goldman ID
    Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D; Hilliard SL
    Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative studies on the pharmacokinetics of hydrophilic prolinedithiocarbamate, sarcosinedithiocarbamate and the less hydrophilic diethyldithiocarbamate.
    Frank N; Christmann A; Frei E
    Toxicology; 1995 Jan; 95(1-3):113-22. PubMed ID: 7529951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
    Golab J; Zagozdzon R; Kozar K; Kaminski R; Giermasz A; Stoklosa T; Lasek W; Jakobisiak M
    Oncol Rep; 2000; 7(1):177-81. PubMed ID: 10601614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing- and sequence-dependent synergism between etoposide and methotrexate or etoposide, methotrexate and 5-fluorouracil in advanced leukemia L1210.
    Osswald H; Herrmann R; Youssef M
    Cancer Lett; 1985 Dec; 29(3):277-82. PubMed ID: 4075296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of acetyl-L-carnitine on leukemia L1210 resistant to mitoxantrone.
    Niang M; Mĕlka M
    Acta Medica (Hradec Kralove); 2000; 43(4):125-8. PubMed ID: 11294129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proline dithiocarbamate inhibits N-nitrosodiethylamine induced liver carcinogenesis.
    Hadjiolov D; Frank N; Moog C; Spirov K
    J Cancer Res Clin Oncol; 1992; 118(6):401-4. PubMed ID: 1377694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice.
    Valeriote F; Medoff G; Tolen S; Dieckman J
    J Natl Cancer Inst; 1984 Aug; 73(2):475-82. PubMed ID: 6589439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
    Góra-Tybor J; Robak T
    Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
    Fujimoto S; Ogawa M
    Cancer Chemother Pharmacol; 1982; 8(2):157-62. PubMed ID: 7105379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
    Góra-Tybor J; Robak T; Warzocha K; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination treatment with adriamycin and methotrexate on the survival time of leukemic (L 1210) mice.
    Miyakawa A; Padarathsingh M; Vadlamudi S; Goldin A
    Chemotherapy; 1973; 19(1):38-46. PubMed ID: 4747574
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia.
    Kimler BF; Hacker MP
    Cancer Clin Trials; 1981; 4(2):173-6. PubMed ID: 7249253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 17. Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors.
    Ferguson K; Boschelli D; Hoffman P; Oronsky A; Whiteley J; Webber S; Galivan J; Freishiem J; Hynes J; Kerwar SS
    Cancer Chemother Pharmacol; 1989; 25(3):173-6. PubMed ID: 2598407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.
    Osswald H; Youssef M
    J Cancer Res Clin Oncol; 1986; 111(2):137-40. PubMed ID: 2939092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.